Neurobiology of cognitive impairment in Parkinson’s disease

References

• Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov. Disord. 27(1), 8–30 (2012).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Synucleinopathies. In: Encyclopedia of Movement Disorders, Volume 3. Kompoliti K, Verhagen-Metman L (Eds). Academic Press, Oxford, UK, 203–207 (2010).
   Google Scholar
• Non-Motor Symptoms of Parkinson’s Disease. Chaudhuri KR, Tolosa E, Schapira A, Poewe W (Eds). Oxford University Press, Oxford, UK (2009).
   Google Scholar
• Tolosa E, Santamaria J, Gaig C, Compta Y. Nonmotor aspects of Parkinson’s disease. In: Movement Disorders 4. Schapira AHV, Lang AET, Fahn S (Eds). Saunders-Elsevier, Philadelphia, PA, USA, 229–251 (2010).
   Google Scholar
• Charcot J-M. De la paralysie agitante. Oeuvres Complétes: Leçons sur les maladies du systéme nerveux. Vol 1. Paris: Bureaux du Progrés Mèdical, 1872; On Parkinson’s disease. Lectures on the diseases of the nervous system. G. Sigerson, trans. New Sydenham Society, London, UK (1877).
   Google Scholar
• Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 11(8), 697–707 (2012).
   PubMed Web of Science ®Google Scholar
• Meireles J, Massano J. Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and management. Front. Neurol. 3, 1–15 (2012).
   PubMedGoogle Scholar
• Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D. Cognitive impairment in nondemented Parkinson’s disease. Mov. Disord. 26(14), 2483–2495 (2011).
   PubMed Web of Science ®Google Scholar
• Vossius C, Larsen JP, Janvin C, Aarsland D. The economic impact of cognitive impairment in Parkinson’s disease. Mov. Disord. 26(8), 1541–1544 (2011).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Williams-Gray C et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75(12), 1062–1069 (2010).
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Tröster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27(3), 349–356 (2012).
   PubMed Web of Science ®Google Scholar
• Perez F, Helmer C, Foubert-Samier A et al. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers Dement. 8(6), 463–469 (2012).
   PubMed Web of Science ®Google Scholar
• Riedel O, Klotsche J, Spottke A et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J. Neurol. 257(7), 1073–1082 (2010).
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837–844 (2008).
   PubMed Web of Science ®Google Scholar
• Perez F, Helmer C, Foubert-Samier A, Auriacombe S, Dartigues JF, Tison F. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers. Dement. 8(6):463-9 (2012).
   PubMedGoogle Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov. Disord. 20(10), 1255–1263 (2005).
   PubMed Web of Science ®Google Scholar
• Poletti M, Frosini D, Pagni C et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 83(6), 601–606 (2012).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13), 1121–1126 (2009).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 61(12), 1906–1911 (2004).
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A et al. The distinct cognitive syndromes of Parkinson’s disease: 5-year follow-up of the CamPaIGN cohort. Brain 132(Pt 11), 2958–2969 (2009).
   PubMed Web of Science ®Google Scholar
• Green J, McDonald WM, Vitek JL et al. Cognitive impairments in advanced PD without dementia. Neurology 59(9), 1320–1324 (2002).
   PubMed Web of Science ®Google Scholar
• Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov. Disord. 27(7), 858–863 (2012).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Brønnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatr. 78(1), 36–42 (2007).
   PubMed Web of Science ®Google Scholar
• Verbaan D, van Rooden SM, Visser M, Marinus J, Emre M, van Hilten JJ. Psychotic and compulsive symptoms in Parkinson’s disease. Mov. Disord. 24(5), 738–744 (2009).
   PubMed Web of Science ®Google Scholar
• de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol. 62(8), 1265–1269 (2005).
   PubMedGoogle Scholar
• Williams-Gray CH, Goris A, Saiki M et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J. Neurol. 256(3), 493–498 (2009).
   PubMed Web of Science ®Google Scholar
• Camicioli R, Rajput A, Rajput M et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: relationship to dementia and hallucinations. Mov. Disord. 20(8), 989–994 (2005).
   PubMed Web of Science ®Google Scholar
• Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J. Geriatr. Psychiatry Neurol. 22(3), 166–170 (2009).
   PubMed Web of Science ®Google Scholar
• Ballard CG, Aarsland D, McKeith I et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59(11), 1714–1720 (2002).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann. Neurol. 64(Suppl. 2), S81–S92 (2008).
   PubMed Web of Science ®Google Scholar
• Meireles J, Massano J. Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and management. Front. Neurol. 3, 88 (2012).
   PubMedGoogle Scholar
• Cognitive Impairment and Dementia in Parkinson’s Disease. Emre M (Ed.). Oxford University Press, Oxford, UK (2010).
   Google Scholar
• Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 22(12), 1689–707; quiz 1837 (2007).
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain 129(Pt 3), 729–735 (2006).
   PubMed Web of Science ®Google Scholar
• Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatr. 82(9), 1033–1037 (2011).
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García-Sánchez C, Gironell A; Trapecio Group Study. Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov. Disord. 23(13), 1889–1896 (2008).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov. Disord. 24(15), 2175–2186 (2009).
   PubMed Web of Science ®Google Scholar
• Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 122(2), 117–135 (2011).
   PubMed Web of Science ®Google Scholar
• Psychiatry of Parkinson’s Disease. Ebmeier KP, O’Brien JT, Taylor J-P (Eds). S. Karger, Basel, Switzerland (2012).
   Google Scholar
• Morgante L, Colosimo C, Antonini A et al.; PRIAMO Study Group. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J. Neurol. Neurosurg. Psychiatr. 83(1), 76–82 (2012).
   PubMed Web of Science ®Google Scholar
• Gagnon JF, Bertrand JA, Génier Marchand D. Cognition in rapid eye movement sleep behavior disorder. Front. Neurol. 3, 82 (2012).
   PubMedGoogle Scholar
• Kotagal V, Albin RL, Müller ML et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 71(4), 560–568 (2012).
   PubMed Web of Science ®Google Scholar
• Magen I, Chesselet M-F. Mouse models of cognitive deficits due to α-synuclein pathology. J. Parkinson’s Dis. 1, 217–227 (2011).
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition) Text Revision. American Psychiatric Association, Washington DC, USA (2000).
   Google Scholar
• Dubois B, Burn D, Goetz C et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22(16), 2314–2324 (2007).
   PubMed Web of Science ®Google Scholar
• Dujardin K, Dubois B, Tison F et al.; EXECUTIVE study group. Parkinson’s disease dementia can be easily detected in routine clinical practice. Mov. Disord. 25(16), 2769–2776 (2010).
   PubMed Web of Science ®Google Scholar
• Barton B, Grabli D, Bernard B et al. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson’s disease with dementia. Mov. Disord. 27(2), 248–253 (2012).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C et al. Dementia associated with Parkinson’s disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat. Disord. 17(8), 621–624 (2011).
   PubMed Web of Science ®Google Scholar
• Docherty MJ, Burn DJ. Parkinson’s disease dementia. Curr. Neurol. Neurosci. Rep. 10(4), 292–298 (2010).
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 75(14), 1270–1276 (2010).
   PubMed Web of Science ®Google Scholar
• Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Predictors of survival in patients with Parkinson disease. Arch. Neurol. 69(5), 601–607 (2012).
   PubMedGoogle Scholar
• Caviness JN, Driver-Dunckley E, Connor DJ et al. Defining mild cognitive impairment in Parkinson’s disease. Mov. Disord. 22(9), 1272–1277 (2007).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Roberts RO, Knopman DS et al. Mild cognitive impairment: ten years later. Arch. Neurol. 66(12), 1447–1455 (2009).
   PubMed Web of Science ®Google Scholar
• Loewenstein DA, Greig MT, Schinka JA et al. An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers. Dement. 8(3), 172–179 (2012).
   PubMed Web of Science ®Google Scholar
• Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson’s disease: subtypes and motor characteristics. Parkinsonism Relat. Disord. 16(3), 177–180 (2010).
   PubMed Web of Science ®Google Scholar
• Tröster AI. A precis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson’s disease and a proposal of preliminary research criteria. J. Int. Neuropsychol. Soc. 8, 1–14 (2011).
   Google Scholar
• Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson’s disease. Mov. Disord. 27(9), 1129–1136 (2012).
   PubMed Web of Science ®Google Scholar
• Dalrymple-Alford JC, Livingston L, MacAskill MR et al. Characterizing mild cognitive impairment in Parkinson’s disease. Mov. Disord. 26(4), 629–636 (2011).
   PubMed Web of Science ®Google Scholar
• Goldman JG, Litvan I. Mild cognitive impairment in Parkinson’s disease. Minerva Med. 102(6), 441–459 (2011).
   PubMed Web of Science ®Google Scholar
• Liepelt-Scarfone I, Graeber S, Feseker A et al. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson’s disease. Parkinsons. Dis. 2011, 540843 (2011).
   PubMedGoogle Scholar
• Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov. Disord. 21(9), 1343–1349 (2006).
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J. Neurol. Neurosurg. Psychiatr. 79(12), 1386–1391 (2008).
   PubMed Web of Science ®Google Scholar
• Han JW, Lee SB, Kim TH et al. Functional impairment in the diagnosis of mild cognitive impairment. Alzheimer Dis. Assoc. Disord. 25(3), 225–229 (2011).
   PubMed Web of Science ®Google Scholar
• Martínez-Horta S, Kulisevsky J. Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”? J. Neural Transm. 118(8), 1185–1190 (2011).
   PubMed Web of Science ®Google Scholar
• Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov. Disord. 26(6), 1042–1048 (2011).
   PubMed Web of Science ®Google Scholar
• Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson’s disease. Annu. Rev. Genomics Hum. Genet. 12, 301–325 (2011).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. The role of α-synuclein in neurodegeneration – an update. Translat. Neurosci. 3, 75–122 (2012).
   Web of Science ®Google Scholar
• Fujioka S, Wszolek ZK. Update on genetics of parkinsonism. Neurodegener. Dis. 10(1–4), 257–260 (2012).
   PubMed Web of Science ®Google Scholar
• Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson’s disease: update. J. Neurol. Neurosurg. Psychiatr. 83(4), 430–436 (2012).
   PubMed Web of Science ®Google Scholar
• Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: genetics and pathogenesis. Annu. Rev. Pathol. 6, 193–222 (2011).
   PubMed Web of Science ®Google Scholar
• Poulopoulos M, Cortes E, Vonsattel JP et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J. Mol. Neurosci. 47(1), 139–143 (2012).
   PubMed Web of Science ®Google Scholar
• Kasten M, Kertelge L, Brüggemann N et al. Nonmotor symptoms in genetic Parkinson disease. Arch. Neurol. 67(6), 670–676 (2010).
   PubMedGoogle Scholar
• Houlden H, Singleton AB. The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol. 124(3), 325–338 (2012).
   PubMed Web of Science ®Google Scholar
• Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55(2), 164–173 (2004).
   PubMed Web of Science ®Google Scholar
• Stamper C, Siegel A, Liang WS et al. Neuronal gene expression correlates of Parkinson’s disease with dementia. Mov. Disord. 23(11), 1588–1595 (2008).
   PubMed Web of Science ®Google Scholar
• Cullen V, Sardi SP, Ng J et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69(6), 940–953 (2011).
   PubMed Web of Science ®Google Scholar
• Almeida MR. Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. Front. Neurol. 3, 65 (2012).
   PubMedGoogle Scholar
• Meeus B, Verstraeten A, Crosiers D et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol. Aging 33(3), 629.e5–629.e18 (2012).
   Google Scholar
• Brockmann K, Srulijes K, Hauser AK et al. GBA-associated PD presents with nonmotor characteristics. Neurology 77(3), 276–280 (2011).
   PubMed Web of Science ®Google Scholar
• Setó-Salvia N, Pagonabarraga J, Houlden H et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson’s disease course. Mov. Disord. 27(3), 393–399 (2012).
   PubMed Web of Science ®Google Scholar
• Setó-Salvia N, Clarimón J, Pagonabarraga J et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch. Neurol. 68(3), 359–364 (2011).
   PubMedGoogle Scholar
• Morley JF, Xie SX, Hurtig HI et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov. Disord. 27(4), 512–518 (2012).
   PubMed Web of Science ®Google Scholar
• Martin WR, Wieler M, Gee M, Camicioli R. Temporal lobe changes in early, untreated Parkinson’s disease. Mov. Disord. 24(13), 1949–1954 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez MJ, Potter E, Shen Q et al. Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer’s disease. Alzheimers. Dement. 8(3), 211–218 (2012).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Doshi J, Koka D et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch. Neurol. 68(12), 1562–1568 (2011).
   PubMed Web of Science ®Google Scholar
• Hong JY, Lee JE, Sohn YH, Lee PH. Neurocognitive and atrophic patterns in Parkinson’s disease based on subjective memory complaints. J. Neurol. 259(8), 1706–1712 (2012).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Dietz N, Duda JE et al. Alzheimer’s disease pattern of brain atrophy predicts cognitive decline in Parkinson’s disease. Brain 135(Pt 1), 170–180 (2012).
   PubMed Web of Science ®Google Scholar
• Camicioli R, Sabino J, Gee M et al. Ventricular dilatation and brain atrophy in patients with Parkinson’s disease with incipient dementia. Mov. Disord. 26(8), 1443–1450 (2011).
   PubMed Web of Science ®Google Scholar
• Apostolova L, Alves G, Hwang KS et al. Hippocampal and ventricular changes in Parkinson’s disease mild cognitive impairment. Neurobiol. Aging 33(9), 2113–2124 (2012).
   PubMed Web of Science ®Google Scholar
• Lee JE, Park B, Song SK, Sohn YH, Park HJ, Lee PH. A comparison of gray and white matter density in patients with Parkinson’s disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov. Disord. 25(1), 28–34 (2010).
   PubMed Web of Science ®Google Scholar
• Melzer TR, Watts R, MacAskill MR et al. Grey matter atrophy in cognitively impaired Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 83(2), 188–194 (2012).
   PubMed Web of Science ®Google Scholar
• Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69(8), 747–754 (2007).
   PubMed Web of Science ®Google Scholar
• Burton EJ, Mukaetova-Ladinska EB, Perry RH, Jaros E, Barber R, O’Brien JT. Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol. Aging 33(7), 1228–1236 (2012).
   PubMed Web of Science ®Google Scholar
• Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B et al. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson’s disease with dementia. Mov. Disord. 24(12), 1740–1746 (2009).
   PubMed Web of Science ®Google Scholar
• Hattori T, Orimo S, Aoki S et al. Cognitive status correlates with white matter alteration in Parkinson’s disease. Hum. Brain Mapp. 33(3), 727–739 (2012).
   PubMed Web of Science ®Google Scholar
• Choi SA, Evidente VG, Caviness JN et al. Are there differences in cerebral white matter lesion burdens between Parkinson’s disease patients with or without dementia? Acta Neuropathol. 119(1), 147–149 (2010).
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat. Rev. Neurol. 7(4), 229–236 (2011).
   PubMed Web of Science ®Google Scholar
• Carlesimo GA, Piras F, Assogna F, Pontieri FE, Caltagirone C, Spalletta G. Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 78(24), 1939–1945 (2012).
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Koeppe RA, Minoshima S et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J. Nucl. Med. 52(6), 848–855 (2011).
   PubMed Web of Science ®Google Scholar
• Hosokai Y, Nishio Y, Hirayama K et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov. Disord. 24(6), 854–862 (2009).
   PubMed Web of Science ®Google Scholar
• Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur. Neurol. 64(2), 65–73 (2010).
   PubMed Web of Science ®Google Scholar
• Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson’s disease dementia. Brain Pathol. 20(3), 646–653 (2010).
   PubMed Web of Science ®Google Scholar
• Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson’s disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 11(8), 679–687 (2012).
   PubMed Web of Science ®Google Scholar
• Nobili F, De Carli F, Frisoni GB et al. SPECT predictors of cognitive decline and Alzheimer’s disease in mild cognitive impairment. J. Alzheimers Dis. 17(4), 761–772 (2009).
   PubMed Web of Science ®Google Scholar
• Kantarci K, Lowe VJ, Boeve BF et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol. Aging 33(9), 2091–2105 (2012).
   PubMed Web of Science ®Google Scholar
• Kasanuki K, Iseki E, Fujishiro H et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J. Neurol. Sci. 314(1–2), 111–119 (2012).
   PubMed Web of Science ®Google Scholar
• Kenny ER, Blamire AM, Firbank MJ, O’Brien JT. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer’s disease. Brain 135(Pt 2), 569–581 (2012).
   PubMed Web of Science ®Google Scholar
• Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 263(1), 226–234 (2012).
   PubMed Web of Science ®Google Scholar
• Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 76(21), 1797–1803 (2011).
   PubMed Web of Science ®Google Scholar
• Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 83(10), 963–969 (2012).
   PubMed Web of Science ®Google Scholar
• Walker Z, Jaros E, Walker RW et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J. Neurol. Neurosurg. Psychiatr. 78(11), 1176–1181 (2007).
   PubMed Web of Science ®Google Scholar
• Wolk DA, Price JC, Saxton JA et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 65(5), 557–568 (2009).
   PubMed Web of Science ®Google Scholar
• Gomperts SN, Locascio JJ, Marquie M et al. Brain amyloid and cognition in Lewy body diseases. Mov. Disord. 27(8), 965–973 (2012).
   PubMed Web of Science ®Google Scholar
• Landau SM, Harvey D, Madison CM et al.; Alzheimer’s Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75(3), 230–238 (2010).
   PubMed Web of Science ®Google Scholar
• Montine TJ, Shi M, Quinn JF et al. CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment. Mov. Disord. 25(15), 2682–2685 (2010).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Xie SX, Hurtig H et al. CSF amyloid {β} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75(12), 1055–1061 (2010).
   PubMed Web of Science ®Google Scholar
• Wallin A, Göthlin M, Gustavsson M et al. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dement. Geriatr. Cogn. Disord. 32(3), 193–197 (2011).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Trautmann E, Otte B et al. α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural Transm. 119(7), 739–746 (2012).
   PubMed Web of Science ®Google Scholar
• Kasuga K, Ikeuchi T. [Cerebrospinal fluid and plasma biomarkers for dementia with Lewy bodies]. Brain Nerve 64(5), 505–513 (2012).
   PubMedGoogle Scholar
• Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov. Disord. 26(8), 1428–1435 (2011).
   PubMed Web of Science ®Google Scholar
• Reesink FE, Lemstra AW, van Dijk KD et al. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J. Alzheimers Dis. 22(1), 87–95 (2010).
   PubMed Web of Science ®Google Scholar
• Engelborghs S, De Vreese K, Van de Casteele T et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29(8), 1143–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Kasuga K, Tokutake T, Ishikawa A et al. Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr. 81(6), 608–610 (2010).
   PubMed Web of Science ®Google Scholar
• Compta Y, Martí MJ, Ibarretxe-Bilbao N et al. Cerebrospinal tau, phospho-tau, and β-amyloid and neuropsychological functions in Parkinson’s disease. Mov. Disord. 24(15), 2203–2210 (2009).
   PubMed Web of Science ®Google Scholar
• Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat. Disord. 17(1), 61–64 (2011).
   PubMed Web of Science ®Google Scholar
• Parnetti L, Tiraboschi P, Lanari A et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 64(10), 850–855 (2008).
   PubMed Web of Science ®Google Scholar
• Bibl M, Esselmann H, Lewczuk P et al. Combined analysis of CSF tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s Disease dementia. Int. J. Alzheimers. Dis. 2010 (2010).
   PubMedGoogle Scholar
• Mulugeta E, Londos E, Hansson O et al. Cerebrospinal fluid levels of sAPPa and sAPPβ in Lewy body and Alzheimer’s disease: clinical and neurochemical correlates. Int. J. Alzheimers. Dis. 2011, 495025 (2011).
   PubMedGoogle Scholar
• Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer’s disease. J. Alzheimers Dis. 27(2), 377–384 (2011).
   PubMed Web of Science ®Google Scholar
• Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem. Int. 55(4), 214–218 (2009).
   PubMed Web of Science ®Google Scholar
• Johansen KK, White LR, Sando SB, Aasly JO. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat. Disord. 16(5), 307–315 (2010).
   PubMed Web of Science ®Google Scholar
• Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson’s disease dementia. Int. J. Geriatr. Psychiatry 26(1), 100–105 (2011).
   PubMed Web of Science ®Google Scholar
• Buongiorno M, Compta Y, Martí MJ. Amyloid-β and t biomarkers in Parkinson’s disease-dementia. J. Neurol. Sci. 310(1–2), 25–30 (2011).
   PubMed Web of Science ®Google Scholar
• Lehnert S, Jesse S, Rist W et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson’s disease dementia. Exp. Neurol. 234(2), 499–505 (2012).
   PubMed Web of Science ®Google Scholar
• Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J. Neural Transm. 119(7), 861–875 (2012).
   PubMed Web of Science ®Google Scholar
• Warr L, Walker Z. Identification of biomarkers in Lewy-body disorders. Q. J. Nucl. Med. Mol. Imaging 56(1), 39–54 (2012).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. In: Dementia in Clinical Practice. Front Neurol Neurosci, Vol 24. Giannakopoulos P, Hof PR (Eds). Karger, Basel, Switzerland, 114–125 (2009).
   Google Scholar
• Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson’s disease. Acta Neuropathol. 118(5), 587–598 (2009).
   PubMed Web of Science ®Google Scholar
• Sonnen JA, Postupna N, Larson EB et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol. 20(3), 654–659 (2010).
   PubMed Web of Science ®Google Scholar
• Beach TG, Adler CH, Lue L et al.; Arizona Parkinson’s Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117(6), 613–634 (2009).
   PubMed Web of Science ®Google Scholar
• Evans JR, Revesz T, Barker RA. Lesions associated with cognitive impairment and dementia. In: Non-Dopamine Lesions in Parkinson’s Disease. Halliday G, Barker RA, Rowe DB (Eds). Oxford University Press, Oxford, UK, 261–287 (2011).
   Google Scholar
• Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59(1), 102–112 (2002).
   PubMed Web of Science ®Google Scholar
• Irwin DJ, White MT, Toledo JB et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72(4), 587–598 (2012).
   PubMed Web of Science ®Google Scholar
• Mattila PM, Rinne JO, Helenius H, Röyttä M. Neuritic degeneration in the hippocampus and amygdala in Parkinson’s disease in relation to Alzheimer pathology. Acta Neuropathol. 98(2), 157–164 (1999).
   PubMed Web of Science ®Google Scholar
• Joelving FC, Billeskov R, Christensen JR, West M, Pakkenberg B. Hippocampal neuron and glial cell numbers in Parkinson’s disease – a stereological study. Hippocampus 16(10), 826–833 (2006).
   PubMed Web of Science ®Google Scholar
• Irwin DJ, White MT, Toledo JB et al Neuropathologic substrates of Parkinson’s disease dementia. Ann. Neurol. 72(4), 587–598 (2012).
   PubMed Web of Science ®Google Scholar
• Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-β deposition in the cerebral cortex in Parkinson’s disease. Mov. Disord. 18(1), 81–86 (2003).
   PubMed Web of Science ®Google Scholar
• Oinas M, Polvikoski T, Sulkava R et al. Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study. J. Alzheimers Dis. 18(3), 677–689 (2009).
   PubMed Web of Science ®Google Scholar
• Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132(Pt 11), 2947–2957 (2009).
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Adler CH, Lahti TJ et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 23(3), 295–297 (2009).
   PubMed Web of Science ®Google Scholar
• Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64(8), 1404–1410 (2005).
   PubMed Web of Science ®Google Scholar
• Compta Y, Parkkinen L, O’Sullivan SS et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134(Pt 5), 1493–1505 (2011).
   PubMed Web of Science ®Google Scholar
• Libow LS, Frisina PG, Haroutunian V, Perl DP, Purohit DP. Parkinson’s disease dementia: a diminished role for the Lewy body. Parkinsonism Relat. Disord. 15(8), 572–575 (2009).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural Transm. Suppl. 72, 91–104 (2007).
   Google Scholar
• Jellinger KA. Lewy body disorders. In: Degenerative Diseases of the Nervous System. Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (Eds). Springer Science, New York, NY, USA, 270–343 (2007).
   Google Scholar
• Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 115(4), 427–436 (2008).
   PubMed Web of Science ®Google Scholar
• Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74(1), 77–84 (2010).
   PubMed Web of Science ®Google Scholar
• Schneider JA, Arvanitakis Z, Yu L et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 135(10), 3005–3014 (2012).
   PubMed Web of Science ®Google Scholar
• Foster ER, Campbell MC, Burack MA et al. Amyloid imaging of Lewy body-associated disorders. Mov. Disord. 25(15), 2516–2523 (2010).
   PubMed Web of Science ®Google Scholar
• Kotzbauer PT, Cairns NJ, Campbell MC et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch. Neurol. 69(10), 1326–1331 (2012).
   PubMedGoogle Scholar
• Dugger BN, Serrano GE, Sue LI et al.; the Arizona Parkinson’s Disease Consortium. Presence of striatal amyloid plaques in Parkinson’s disease dementia predicts concomitant Alzheimer’s disease: usefulness for amyloid imaging. J. Parkinsons. Dis. 2(1), 57–65 (2012).
   PubMedGoogle Scholar
• Schwartz RS, Halliday GM, Cordato DJ, Kril JJ. Small-vessel disease in patients with Parkinson’s disease: a clinicopathological study. Mov. Disord. 27(12), 1506–1512 (2012).
   PubMed Web of Science ®Google Scholar
• Ghebremedhin E, Rosenberger A, Rüb U et al. Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J. Neuropathol. Exp. Neurol. 69(5), 442–448 (2010).
   PubMed Web of Science ®Google Scholar
• van den Berge SA, Kevenaar JT, Sluijs JA, Hol EM. Dementia in Parkinson’s disease correlates with α-synuclein pathology but not with cortical astrogliosis. Parkinsons Dis. 2012, 420957 (2012).
   PubMedGoogle Scholar
• McKeith IG, Dickson DW, Lowe J et al.; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12), 1863–1872 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Londos E, Ballard C. Parkinson’s disease dementia and dementia with Lewy bodies: different aspects of one entity. Int. Psychogeriatr. 21(2), 216–219 (2009).
   PubMedGoogle Scholar
• Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J. Cell. Mol. Med. 16(6), 1166–1183 (2012).
   PubMed Web of Science ®Google Scholar
• Kraybill ML, Larson EB, Tsuang DW et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64(12), 2069–2073 (2005).
   PubMed Web of Science ®Google Scholar
• Deramecourt V, Bombois S, Maurage CA et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 65(3), 278–288 (2006).
   PubMed Web of Science ®Google Scholar
• Alafuzoff I, Ince PG, Arzberger T et al. Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 117(6), 635–652 (2009).
   PubMed Web of Science ®Google Scholar
• Fujishiro H, Ferman TJ, Boeve BF et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J. Neuropathol. Exp. Neurol. 67(7), 649–656 (2008).
   PubMed Web of Science ®Google Scholar
• Ince PG. Dementia with Lewy bodies and Parkinson’s disease dementia. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (2nd Edition). Dickson DW, Weller RO (Eds). Blackwell Publishing Ltd., Oxford, UK, 224–237 (2011).
   Google Scholar
• Masliah E. Recent advances in the understanding of the role of synaptic proteins in Alzheimer’s disease and other neurodegenerative disorders. J. Alzheimers Dis. 3(1), 121–129 (2001).
   PubMed Web of Science ®Google Scholar
• Ubhi K, Peng K, Lessig S et al. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neurosci. Lett. 485(3), 222–227 (2010).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Song YJ, Harding AJ. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson’s disease. J. Neural Transm. 118(5), 713–719 (2011).
   PubMed Web of Science ®Google Scholar
• Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 112(3), 253–260 (2006).
   PubMed Web of Science ®Google Scholar
• Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol. Dis. 41(2), 377–384 (2011).
   PubMed Web of Science ®Google Scholar
• Fujishiro H, Iseki E, Higashi S et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci. Lett. 486(1), 19–23 (2010).
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson’s disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat. Disord. 13(Suppl. 3), S221–S224 (2007).
   Google Scholar
• Ballard C, Ziabreva I, Perry R et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67(11), 1931–1934 (2006).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Perry R, Larsen JP et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J. Clin. Psychiatry 66(5), 633–637 (2005).
   PubMed Web of Science ®Google Scholar
• Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov. Disord. 22(Suppl. 17), S351–S357 (2007).
   PubMed Web of Science ®Google Scholar
• Sharp SI, Ballard CG, Ziabreva I et al. Cortical serotonin 1 A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord. 26(4), 330–338 (2008).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J. Neural Transm. (2012) (Epub ahead of print).
   Google Scholar
• Adler CH, Beach TG. Variability of diffuse plaques and amyloid angiopathy in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol. 120, 831–832 (2010).
   Web of Science ®Google Scholar
• Jellinger KA. Neuropathology in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol. 120(6), 829–30; author reply 831 (2010).
   PubMed Web of Science ®Google Scholar
• Molano J, Boeve B, Ferman T et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 133(Pt 2), 540–556 (2010).
   PubMed Web of Science ®Google Scholar
• Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J. Alzheimers Dis. 19(1), 221–228 (2010).
   PubMed Web of Science ®Google Scholar
• Jicha GA, Parisi JE, Dickson DW et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 63(5), 674–681 (2006).
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Binder L, Counts SE et al. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 123(1), 13–30 (2012).
   PubMed Web of Science ®Google Scholar
• Fujita M, Ichise M, Zoghbi SS et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease. Ann. Neurol. 59(1), 174–177 (2006).
   PubMed Web of Science ®Google Scholar
• Albin RL, Dauer WT. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis? Neurology 79(3), 202–203 (2012).
   PubMed Web of Science ®Google Scholar
• Shimada H, Hirano S, Shinotoh H et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73(4), 273–278 (2009).
   PubMed Web of Science ®Google Scholar
• Francis PT. Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. J. Neurol. 256(Suppl. 3), 280–285 (2009).
   PubMed Web of Science ®Google Scholar
• Shiozaki K, Iseki E, Uchiyama H et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr. 67(2), 209–213 (1999).
   PubMed Web of Science ®Google Scholar
• Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70(16 Pt 2), 1470–1477 (2008).
   PubMed Web of Science ®Google Scholar
• McMillan PJ, White SS, Franklin A et al. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson’s disease and Alzheimer’s disease. Brain Res. 1373, 240–252 (2011).
   PubMed Web of Science ®Google Scholar
• Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers. Dement. 8(1), 1–13 (2012).
   PubMed Web of Science ®Google Scholar
• Montine TJ, Phelps CH, Beach TG et al.; National Institute on Aging; Alzheimer’s Association. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 123(1), 1–11 (2012).
   PubMed Web of Science ®Google Scholar
• Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann. Neurol. 72(1), 41–52 (2012).
   PubMed Web of Science ®Google Scholar
• van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci. Ther. 17(5), 428–441 (2011).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med. 351(24), 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Chitnis S, Rao J. Rivastigmine in Parkinson’s disease dementia. Expert Opin. Drug Metab. Toxicol. 5(8), 941–955 (2009).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis. Am. J. Alzheimers. Dis. Other Demen. 26(6), 443–449 (2011).
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Okamura N, Funaki Y et al. Cholinergic deficit and response to donepezil therapy in Parkinson’s disease with dementia. Eur. Neurol. 68(3), 137–143 (2012).
   PubMed Web of Science ®Google Scholar
• Emre M, Tsolaki M, Bonuccelli U et al.; 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(10), 969–977 (2010).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8(7), 613–618 (2009).
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst. Rev. 3, CD006504 (2012).
   PubMed Web of Science ®Google Scholar
• Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality-of-life and the effect of memantine in dementia with Lewy bodies and Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord. 32(4), 227–234 (2011).
   PubMed Web of Science ®Google Scholar
• Graff-Radford J, Boeve BF, Pedraza O et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 135(Pt 8), 2470–2477 (2012).
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Allen LA et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am. J. Psychiatry 168(10), 1066–1074 (2011).
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Rubino JT, Allen LA et al. Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson’s disease. J. Consult. Clin. Psychol. 80(4), 694–699 (2012).
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10), 886–892 (2009).
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26(Suppl. 3), S42–S80 (2011).
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(6), 573–580 (2010).
   PubMed Web of Science ®Google Scholar
• Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. The role of the dopaminergic system in mood, motivation and cognition in Parkinson’s disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J. Neurol. Sci. 320(1–2), 121–126 (2012).
   PubMed Web of Science ®Google Scholar
• McDermott CL, Gray SL. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. Ann. Pharmacother. 46(4), 599–605 (2012).
   PubMed Web of Science ®Google Scholar
• Drach LM. [Drug treatment of dementia with Lewy bodies and Parkinson’s disease dementia–common features and differences]. Med. Monatsschr. Pharm. 34(2), 47–52; quiz 53 (2011).
   PubMedGoogle Scholar
• Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P. Clinical trials of dementia with lewy bodies and Parkinson’s disease dementia. Curr. Neurol. Neurosci. Rep. 12(5), 492–501 (2012).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79(4), 368–376 (2008).
   PubMed Web of Science ®Google Scholar